Employment in the UK’s gene therapy business, and other advanced therapy medicinal products (ATMPs) was the only part of the biopharma sector to witness an increase in jobs in the past five years, according to a government report published on August 4 2017.
ATMPs, which include gene therapy, somatic cell therapy and tissue engineered products, had more than a 30% rise in employment between 2011 and 2016, according to the revised official annual update on the state of the biopharma and medical technology industries published by the Department of Health, the Department for Business, Energy and Industrial Strategy and the Office for Life Sciences.
At the same time the sector’s small molecules and vaccines business saw a decline in both staff employment and turnover, the revised report revealed.
The report said that most of the jobs in the life science industry, core biopharma and medical technology are found in the south east of England.
Some 39% of all life science employees are in the south east and east of England, it said.
The 2016 report, the eighth annual state-of-the-art report of its kind, was originally published in April 2017, but was revised in August following editing changes to remove errors and improve its language.